Skip to main content
RPG Life Sciences Limited logo

RPG Life Sciences Limited — Investor Relations & Filings

Ticker · RPGLIFE ISIN · INE105J01010 LEI · 335800O9C9JKWKXY5Y66 BSE.NS Manufacturing
Open in API
Filings indexed 812 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country IN India
Listing BSE.NS RPGLIFE

About RPG Life Sciences Limited

https://www.rpglifesciences.com

RPG Life Sciences Limited is an integrated pharmaceutical enterprise engaged in the development, manufacturing, and marketing of a diverse range of generic and branded formulations, as well as Active Pharmaceutical Ingredients (APIs). The company operates across several therapeutic segments, including nephrology, oncology, cardiology, rheumatology, and gastroenterology. It maintains a significant presence in the immunosuppressant market, providing critical medications for transplant recipients. With a focus on research and development, the organization produces complex molecules and finished dosages that cater to both domestic and international healthcare markets. Its manufacturing facilities adhere to stringent global quality standards, enabling the supply of essential medicines to regulated and semi-regulated markets worldwide. The portfolio includes a mix of legacy brands and specialty products designed to address chronic and acute medical conditions.

Recent filings

Filing Released Lang Actions
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Regulatory Filings Classification · 85% confidence The document is a letter dated May 22, 2026, from RPG Life Sciences to India’s stock exchanges under SEBI LODR Reg. 30, notifying the scheduling of an Annual Investor Conference on May 26, 2026. It contains no financial results, data disclosures, or presentation materials—it simply announces an event. This is a general regulatory notice/filing that does not fit a more specific category (e.g., earnings release, capital update, board change). Therefore, it falls under Regulatory Filings (RNS).
2026-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 75% confidence The document is a formal disclosure to stock exchanges under SEBI Regulation 30 announcing details of an upcoming Annual Investor Conference. It does not contain financial results or substantive report content but is a regulatory announcement of an investor event. This falls under the general “Regulatory Filings” category for miscellaneous compliance disclosures (RNS).
2026-05-22 English
Intimation of Annual Secretarial Compliance Report for the year ended March 31, 2026.
Regulatory Filings Classification · 90% confidence The document is an Annual Secretarial Compliance Report filed by RPG Life Sciences to the stock exchanges under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a compliance certificate prepared by Practicing Company Secretaries and submitted to satisfy listing obligations. It does not present financial statements or audit opinions, nor does it announce dividend, management changes, or other categories. It therefore falls under the general regulatory filings category as a compliance document (RNS).
2026-05-15 English
The Company informed the Exchange about Transcript of Earnings Call.
Regulatory Filings
2026-05-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2026-05-08 English
Updates
Annual Report Classification · 95% confidence The document contains an official letter from RPG Life Sciences Limited addressed to the National Stock Exchange of India and BSE Limited, dated May 6, 2026, regarding the submission of financial results for the quarter and year ended March 31, 2026. It includes detailed information about the audited financial results, the auditor's report with an unmodified opinion, and the declaration by the CFO. The document also reports the outcome of the Board Meeting held on April 29, 2026, which approved the audited financial results, recommended dividends, and announced the appointment of an additional independent director. The presence of the full auditor's report, detailed financial results, and management's responsibilities indicates this is a comprehensive financial report for the fiscal year ending March 31, 2026. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K equivalent) or a comprehensive financial results report. Given the Indian context and the detailed audited financial results for the full fiscal year, the best fitting category is Annual Report (10-K).
2026-05-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.